Patients with COVID-19 pneumonia and lung fibrosis COVID-19 Pneumonia Lung fibrosis Nintedanib Antifibrotic Oxygenation Chest radiograph Mortality
Conditions
Interventions
Patients with COVID-19 pneumonia and lung fibrosis treated with nintedanib at least 5 days,Patients with COVID-19 pneumonia and lung fibrosis treated with standand medications (no nintedanib)
Treatment,Treatment
Nintedanib group,Control group
Sponsors
Faculty of Medicine, Thammasat University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age 18 years or more, 2. Diagnosis of COVID-19 confirmed by RT-PCR test for SAR-CoV-2, 3. Diagnosis of pneumonia confirmed by chest imaging, 4. Hospital admission at Thammasat University Hospital, 5. Treatment with nintedanib or standard treatment
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Oxygenation improvement at 60 days after treatment Number (%),Chest X-ray improvement at 60 days after treatment Number (%),Mortality rate at 60 days after treatment Number (%) | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of hospital stay at the end of study days,SpO2/FiO2 ratio difference between before and after treatment at the end of study number | — |
Countries
Thailand
Contacts
Public ContactNarongkorn Saiphoklang
Faculty of Medicine, Thammasat University
Outcome results
None listed